Abstract PS1-08-25: Equivalent survival benefits from first-line and second-line use of CDK4/6 inhibitors in HR+/HER2- advanced breast cancer: A computational analysis of phase 3 trials
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Authors: N. Schlachter, L. A. Carey, A. Palmer
Institution: University of North Carolina at Chapel Hill
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129249058
Cites:
Cited by:
Related to: